Bavarian Nordic — Juni 2017
-
Test
-
Hoppet her til morgen skyldes først og fremmest nyheden om at den amerikanske regering nu vil bestille frysetørret IMVAMUNE hos BAVA.
Dette var ventet, men er nu bekræftet.. og betyder sikringen af i hvert fald 2/3 af årets indtægter (+ den Priority Review Voucher som er $100-350 mio. værd!).. samtidig med at man reelt får sikret en længere årrække med leveringer til US.
Dette er som sagt ventet, men ikke desto mindre y
derst positivt!! -
Fra WHOs site http://www.afro.who.int/en/ebola/ebola-situation-reports.html "Ebola Situation report: 13 June 2017":
"
On 12 June 2017, no new confirmed or probable cases were reported. Since the last situation update on 9 June, 33 alerts have been reported and investigated, of which 1 currently fulfils the suspected case definition, a sample has been taken for laboratory analysis and results are pending. The last confirmed case was isolated on.. -
..17 May 2017 and tested negative for EVD by PCR for the second time on 21 May 2017.
"
Så 1 testes lige nu - den senest bekræftede Ebola smittede var 17. maj.
De laver selv den - altid sjove - statistiske vurdering, at "As of the reporting date, 90% of simulated scenarios predict no further cases in the next 30 days." -
Sukkeralf, på ClinicalTrials.gov kan jeg, ved de to "tisotumab"-studier, kun finde at "exclusion criteria - Cervical carcinoma of Stage 1B or less." Hvor finder du protokollerne henne?
-
-
@Claus1: Mange tak for et rigtig informativt link om Bava. Ingen tvivl om de selv tror rigtig meget på Prostvac :-), men også den øvrige pipeline var rar lige at få listet op
-
Ja, RSV lyder som et marked de kan tjene store summer på. Næsten mere interessant end Prostvac selvom det kun er phase 2. Jeg kunne godt tænke mig at vide om deres forventninger til salg af koppevacciner udenfor USA. Har dette spørgsmål været oppe at vende?
-
BAVARIAN NORDIC A/S BAVA.CO: COWEN AND COMPANY RAISES TARGET PRICE TO DKK 400 FROM DKK 350 - Reuters News
-
Positive phase 2 resultater fra Zealand på Glepaglutide
-
Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome
• Glepaglutide* is a novel long-acting GLP-2 analogue
• Reduction in fecal wet weight output of 30% and 23% in the two highest dose groups
• Increases in gastrointestinal fluid and energy absorption observed
• The dose response supports the further clinical development of glepaglutide
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind